Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.57 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14477502 | 1.00 | GLP1R (0.57) | GLP1RC3AR1NOD1MEN1KMT2A | |
| SCHEMBL14217286 | 0.97 | GLP1R (0.53) | GLP1RC3AR1NOD1MEN1KMT2A | |
| SCHEMBL21172251 | 0.96 | GLP1R (0.62) | GLP1RC3AR1NOD1MEN1KMT2A | |
| SCHEMBL14217280 | 0.94 | GLP1R (0.58) | GLP1RC3AR1NOD1MEN1KMT2A | |
| SCHEMBL14217386 | 0.91 | GLP1R (0.53) | GLP1RC3AR1NOD1MEN1KMT2A | |
| SCHEMBL21172259 | 0.90 | GLP1R (0.55) | GLP1RC3AR1NOD1FOLH1EPHX2 | |
| SCHEMBL16140674 | 0.90 | GLP1R (0.55) | GLP1RC3AR1NOD1FOLH1EPHX2 | |
| SCHEMBL14998096 | 0.90 | GLP1R (0.55) | GLP1RC3AR1NOD1FOLH1EPHX2 | |
| SCHEMBL19069728 | 0.90 | GLP1R (0.55) | GLP1RC3AR1NOD1FOLH1EPHX2 | |
| SCHEMBL16472579 | 0.90 | GLP1R (0.52) | GLP1RC3AR1NOD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981282-B1 | GROWTH HORMONE COMPOUND FORMULATION | NOVO NORDISK HEALTHCARE AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| EP-2525834-B1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-8779109-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | GLP1R 99/4885C3AR1 1465/4885NOD1 4656/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | GLP1R 101/4885C3AR1 1771/4885NOD1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.